APA (7th ed.) Citation

Sekyonda, Z., Abonga, C., Delianides, C. A., Oshabaheebwa, S., Little, J. A., Suster, M. A., . . . Gurkan, U. A. (2023). Voxelotor and Red Blood Cell Pyruvate Kinase Activator Affect Clot Strength in Sickle Cell Disease. Blood, 142(Supplement 1), 1114. https://doi.org/10.1182/blood-2023-187577

Chicago Style (17th ed.) Citation

Sekyonda, Zoe, Calvin Abonga, Christopher A. Delianides, Solomon Oshabaheebwa, Jane A. Little, Michael A. Suster, Pedram Mohseni, and Umut A. Gurkan. "Voxelotor and Red Blood Cell Pyruvate Kinase Activator Affect Clot Strength in Sickle Cell Disease." Blood 142, no. Supplement 1 (2023): 1114. https://doi.org/10.1182/blood-2023-187577.

MLA (9th ed.) Citation

Sekyonda, Zoe, et al. "Voxelotor and Red Blood Cell Pyruvate Kinase Activator Affect Clot Strength in Sickle Cell Disease." Blood, vol. 142, no. Supplement 1, 2023, p. 1114, https://doi.org/10.1182/blood-2023-187577.